申请人:Board of Regents, The University of Texas System
公开号:US20190298729A1
公开(公告)日:2019-10-03
The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of transcription activating proteins such as CBP and P300 for the treatment or prevention of diseases such as proliferative diseases, inflammatory disorders, autoimmune diseases, and fibrotic diseases.
本公开涉及杂环化合物和方法,这些方法可能作为转录激活蛋白(如CBP和P300)的抑制剂,用于治疗或预防增殖性疾病、炎症性疾病、自身免疫疾病和纤维化疾病。